Fig. 5: Mutational spectrum of the top 20 genes in 10 HER2 amplification-negative patients treated with pyrotinib.

CR complete response, ECD extracellular domain, PD progressive disease, PR partial response, SD stable disease, TK tyrosine kinase domain.